Amylyx Pharmaceuticals (AMLX) Common Equity: 2021-2025
Historic Common Equity for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Sep 2025 value amounting to $332.0 million.
- Amylyx Pharmaceuticals' Common Equity rose 69.21% to $332.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $332.0 million, marking a year-over-year increase of 69.21%. This contributed to the annual value of $164.8 million for FY2024, which is 61.99% down from last year.
- Amylyx Pharmaceuticals' Common Equity amounted to $332.0 million in Q3 2025, which was up 97.76% from $167.9 million recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' Common Equity ranged from a high of $433.4 million in Q4 2023 and a low of -$151.2 million during Q4 2021.
- Moreover, its 3-year median value for Common Equity was $324.4 million (2024), whereas its average is $294.4 million.
- In the last 5 years, Amylyx Pharmaceuticals' Common Equity surged by 325.32% in 2022 and then slumped by 61.99% in 2024.
- Amylyx Pharmaceuticals' Common Equity (Quarterly) stood at -$151.2 million in 2021, then spiked by 325.32% to $340.6 million in 2022, then increased by 27.25% to $433.4 million in 2023, then tumbled by 61.99% to $164.8 million in 2024, then soared by 69.21% to $332.0 million in 2025.
- Its last three reported values are $332.0 million in Q3 2025, $167.9 million for Q2 2025, and $201.4 million during Q1 2025.